Spondyloarthropathies News

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

Although the seroprevalence of SARS-CoV-2 in patients with immune-mediated inflammatory diseases is comparable to the general population, increased systemic inflammation among these patients is linked to symptomatic COVID-19, according to researchers.

Women demonstrate higher axial spondyloarthritis disease burden, and more peripheral symptoms, than men, according to data published in The Journal of Clinical Rheumatology.

The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market.

Proactive therapeutic drug monitoring vs. standard therapy did not significantly improve clinical remission rates over 30 weeks in patients with immune-mediated inflammatory diseases initiating Remicade therapy, according to study results.

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

Maternal ankylosing spondylitis is associated with a 2.02-times higher likelihood of Kawasaki disease in the offspring, according to a research letter published in JAMA Network Open.

Experimental studies indicate that sleep loss can lead to elevated concentrations of proinflammatory cytokines and enhance the perception of pain among patients with immune-mediated inflammatory diseases, according to a speaker here.

Rituximab was associated with more severe COVID-19 in patients with inflammatory rheumatic and musculoskeletal diseases, according to data published in The Lancet Rheumatology.

Patients with inflammatory rheumatic disease, but especially those with autoimmune conditions, as well as those treated with rituximab, may be at greater risk for severe COVID-19 pneumonia than the general population, according to data.